FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4308174390> ?p ?o ?g. }

• W4308174390 endingPage "9" @default.
• W4308174390 startingPage "1" @default.
• W4308174390 abstract "OBJECTIVE MRI-guided low-intensity focused ultrasound (FUS) has been shown to reversibly open the blood-brain barrier (BBB), with the potential to deliver therapeutic agents noninvasively to target brain regions in patients with Alzheimer’s disease (AD) and other neurodegenerative conditions. Previously, the authors reported the short-term safety and feasibility of FUS BBB opening of the hippocampus and entorhinal cortex (EC) in patients with AD. Given the need to treat larger brain regions beyond the hippocampus and EC, brain volumes and locations treated with FUS have now expanded. To evaluate any potential adverse consequences of BBB opening on disease progression, the authors report safety, imaging, and clinical outcomes among participants with mild AD at 6–12 months after FUS treatment targeted to the hippocampus, frontal lobe, and parietal lobe. METHODS In this open-label trial, participants with mild AD underwent MRI-guided FUS sonication to open the BBB in β-amyloid positive regions of the hippocampus, EC, frontal lobe, and parietal lobe. Participants underwent 3 separate FUS treatment sessions performed 2 weeks apart. Outcome assessments included safety, imaging, neurological, cognitive, and florbetaben β-amyloid PET. RESULTS Ten participants (range 55–76 years old) completed 30 separate FUS treatments at 2 participating institutions, with 6–12 months of follow-up. All participants had immediate BBB opening after FUS and BBB closure within 24–48 hours. All FUS treatments were well tolerated, with no serious adverse events related to the procedure. All 10 participants had a minimum of 6 months of follow-up, and 7 participants had a follow-up out to 1 year. Changes in the Alzheimer’s Disease Assessment Scale–cognitive and Mini-Mental State Examination scores were comparable to those in controls from the Alzheimer’s Disease Neuroimaging Initiative. PET scans demonstrated an average β-amyloid plaque of 14% in the Centiloid scale in the FUS-treated regions. CONCLUSIONS This study is the largest cohort of participants with mild AD who received FUS treatment, and has the longest follow-up to date. Safety was demonstrated in conjunction with reversible and repeated BBB opening in multiple cortical and deep brain locations, with a concomitant reduction of β-amyloid. There was no apparent cognitive worsening beyond expectations up to 1 year after FUS treatment, suggesting that the BBB opening treatment in multiple brain regions did not adversely influence AD progression. Further studies are needed to determine the clinical significance of these findings. FUS offers a unique opportunity to decrease amyloid plaque burden as well as the potential to deliver targeted therapeutics to multiple brain regions in patients with neurodegenerative disorders." @default.
• W4308174390 created "2022-11-08" @default.
• W4308174390 creator A5000886350 @default.
• W4308174390 creator A5002874131 @default.
• W4308174390 creator A5004390437 @default.
• W4308174390 creator A5012086700 @default.
• W4308174390 creator A5027250646 @default.
• W4308174390 creator A5029728915 @default.
• W4308174390 creator A5032262064 @default.
• W4308174390 creator A5041002118 @default.
• W4308174390 creator A5049078993 @default.
• W4308174390 creator A5049973001 @default.
• W4308174390 creator A5054950718 @default.
• W4308174390 creator A5064135529 @default.
• W4308174390 creator A5064607755 @default.
• W4308174390 creator A5066444123 @default.
• W4308174390 creator A5072392758 @default.
• W4308174390 creator A5077348743 @default.
• W4308174390 creator A5082880232 @default.
• W4308174390 creator A5084347790 @default.
• W4308174390 creator A5090528055 @default.
• W4308174390 date "2022-11-01" @default.
• W4308174390 modified "2023-10-16" @default.
• W4308174390 title "Focused ultrasound–mediated blood-brain barrier opening in Alzheimer’s disease: long-term safety, imaging, and cognitive outcomes" @default.
• W4308174390 cites W1847168837 @default.
• W4308174390 cites W1953027527 @default.
• W4308174390 cites W2008871739 @default.
• W4308174390 cites W2015484447 @default.
• W4308174390 cites W2067076937 @default.
• W4308174390 cites W2069440543 @default.
• W4308174390 cites W2098265084 @default.
• W4308174390 cites W2101504183 @default.
• W4308174390 cites W2108277337 @default.
• W4308174390 cites W2115017507 @default.
• W4308174390 cites W2124030567 @default.
• W4308174390 cites W2131103601 @default.
• W4308174390 cites W2131358222 @default.
• W4308174390 cites W2144646585 @default.
• W4308174390 cites W2156311276 @default.
• W4308174390 cites W2169076271 @default.
• W4308174390 cites W2171808809 @default.
• W4308174390 cites W2187760945 @default.
• W4308174390 cites W2198267160 @default.
• W4308174390 cites W2414725059 @default.
• W4308174390 cites W2771503729 @default.
• W4308174390 cites W2801229775 @default.
• W4308174390 cites W2802878582 @default.
• W4308174390 cites W2807207060 @default.
• W4308174390 cites W2891635110 @default.
• W4308174390 cites W2891710133 @default.
• W4308174390 cites W2903032912 @default.
• W4308174390 cites W2921121152 @default.
• W4308174390 cites W2939976595 @default.
• W4308174390 cites W2955305217 @default.
• W4308174390 cites W2962900979 @default.
• W4308174390 cites W3000726342 @default.
• W4308174390 cites W3015813913 @default.
• W4308174390 cites W3088158752 @default.
• W4308174390 cites W3092195828 @default.
• W4308174390 cites W3097527510 @default.
• W4308174390 cites W3100915627 @default.
• W4308174390 cites W3120769833 @default.
• W4308174390 cites W3142848788 @default.
• W4308174390 cites W3190263357 @default.
• W4308174390 cites W3207084414 @default.
• W4308174390 cites W3210405129 @default.
• W4308174390 cites W4205910310 @default.
• W4308174390 doi "https://doi.org/10.3171/2022.9.jns221565" @default.
• W4308174390 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36334289" @default.
• W4308174390 hasPublicationYear "2022" @default.
• W4308174390 type Work @default.
• W4308174390 citedByCount "10" @default.
• W4308174390 countsByYear W43081743902023 @default.
• W4308174390 crossrefType "journal-article" @default.
• W4308174390 hasAuthorship W4308174390A5000886350 @default.
• W4308174390 hasAuthorship W4308174390A5002874131 @default.
• W4308174390 hasAuthorship W4308174390A5004390437 @default.
• W4308174390 hasAuthorship W4308174390A5012086700 @default.
• W4308174390 hasAuthorship W4308174390A5027250646 @default.
• W4308174390 hasAuthorship W4308174390A5029728915 @default.
• W4308174390 hasAuthorship W4308174390A5032262064 @default.
• W4308174390 hasAuthorship W4308174390A5041002118 @default.
• W4308174390 hasAuthorship W4308174390A5049078993 @default.
• W4308174390 hasAuthorship W4308174390A5049973001 @default.
• W4308174390 hasAuthorship W4308174390A5054950718 @default.
• W4308174390 hasAuthorship W4308174390A5064135529 @default.
• W4308174390 hasAuthorship W4308174390A5064607755 @default.
• W4308174390 hasAuthorship W4308174390A5066444123 @default.
• W4308174390 hasAuthorship W4308174390A5072392758 @default.
• W4308174390 hasAuthorship W4308174390A5077348743 @default.
• W4308174390 hasAuthorship W4308174390A5082880232 @default.
• W4308174390 hasAuthorship W4308174390A5084347790 @default.
• W4308174390 hasAuthorship W4308174390A5090528055 @default.
• W4308174390 hasBestOaLocation W43081743901 @default.
• W4308174390 hasConcept C118552586 @default.
• W4308174390 hasConcept C126322002 @default.
• W4308174390 hasConcept C126838900 @default.
• W4308174390 hasConcept C143409427 @default.

• next